Skip to main
RXST
RXST logo

RxSight (RXST) Stock Forecast & Price Target

RxSight (RXST) Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 17%
Buy 17%
Hold 50%
Sell 17%
Strong Sell 0%

Bulls say

RxSight Inc has reported a gross margin of 71.6%, reflecting a substantial year-over-year increase of 980 basis points and exceeding consensus expectations. The company achieved Light Adjustable Lens (LAL) revenue of $28.5 million, marking a 60% increase, while Light Delivery Device (LDD) revenue reached $10.7 million with a 7% rise, both in alignment with consensus figures. Strong performance indicators such as increased LAL utilization alongside a growing LDD installed base suggest potential for sustained double-digit growth and further margin improvements in the future.

Bears say

RxSight Inc. has demonstrated a notable deceleration in LAL utilization, which fell to 9% year-over-year in the fourth quarter of 2024, a significant drop from the 17%-22% growth range observed in the previous five quarters. The company faces challenges in the U.S. intraocular lens (IOL) market, where growth has likely stagnated or declined, potentially influenced by weakened end market conditions and increased competition. Additionally, revised earnings per share estimates for 2025 and 2026 reflect a more pessimistic outlook, indicating potential struggles with profitability and market adoption of their technology.

RxSight (RXST) has been analyzed by 12 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 17% recommend Buy, 50% suggest Holding, 17% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RxSight (RXST) Forecast

Analysts have given RxSight (RXST) a Hold based on their latest research and market trends.

According to 12 analysts, RxSight (RXST) has a Hold consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RxSight (RXST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.